Compare BLZE & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLZE | STRO |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.6M | 85.0M |
| IPO Year | 2021 | 2018 |
| Metric | BLZE | STRO |
|---|---|---|
| Price | $4.78 | $10.37 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 8 |
| Target Price | $9.50 | ★ $18.29 |
| AVG Volume (30 Days) | ★ 816.6K | 123.2K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $141,859,000.00 | $105,646,000.00 |
| Revenue This Year | $16.43 | $63.08 |
| Revenue Next Year | $11.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.73 | N/A |
| 52 Week Low | $3.94 | $5.23 |
| 52 Week High | $10.86 | $21.50 |
| Indicator | BLZE | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 79.98 |
| Support Level | $4.44 | $8.49 |
| Resistance Level | $4.98 | $11.09 |
| Average True Range (ATR) | 0.20 | 0.93 |
| MACD | 0.14 | 0.06 |
| Stochastic Oscillator | 52.99 | 80.57 |
Backblaze Inc provides cloud storage services. The company offers services such as Backblaze B2 Cloud Storage, which enables customers to store data, developers to build applications, and partners to expand their use cases. It is offered as a consumption-based Infrastructure-as-a-Service (IaaS) and serves use cases including backups, multi-cloud, application development, and ransomware protection and Backblaze Computer Backup automatically backs up data from laptops and desktops for businesses and individuals. Geographically, it derives a majority of revenue from the United States and the rest from the United Kingdom, Canada, and Other regions.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.